vs
Clipper Realty Inc.（CLPR）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Clipper Realty Inc.的季度营收约是REGENXBIO Inc.的1.2倍（$37.1M vs $30.3M），Clipper Realty Inc.净利率更高（-30.4% vs -221.3%，领先190.9%），REGENXBIO Inc.同比增速更快（43.0% vs -2.6%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 1.8%）
Clipper Realty Inc.旗下Clipper Equity由大卫·比斯特里瑟和山姆·莱文森牵头成立，在美国纽约与新泽西州拥有超60栋物业，合计数千套住宅单元。该企业最为人熟知的事迹是曾在2007年2月出价13亿美元收购纽约布鲁克林的斯塔雷特城住宅区，该交易曾是当时全球规模最大的房地产交易之一。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
CLPR vs RGNX — 直观对比
营收规模更大
CLPR
是对方的1.2倍
$30.3M
营收增速更快
RGNX
高出45.6%
-2.6%
净利率更高
CLPR
高出190.9%
-221.3%
两年增速更快
RGNX
近两年复合增速
1.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $37.1M | $30.3M |
| 净利润 | $-11.3M | $-67.1M |
| 毛利率 | -5.2% | — |
| 营业利润率 | 21.8% | -190.0% |
| 净利率 | -30.4% | -221.3% |
| 营收同比 | -2.6% | 43.0% |
| 净利润同比 | -938.6% | -31.2% |
| 每股收益（稀释后） | — | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLPRRGNX
| Q4 25 | $37.1M | $30.3M | ||
| Q3 25 | $37.7M | $29.7M | ||
| Q2 25 | $39.0M | $21.4M | ||
| Q1 25 | $39.4M | $89.0M | ||
| Q4 24 | $38.0M | $21.2M | ||
| Q3 24 | $37.6M | $24.2M | ||
| Q2 24 | $37.3M | $22.3M | ||
| Q1 24 | $35.8M | $15.6M |
净利润CLPRRGNX
| Q4 25 | $-11.3M | $-67.1M | ||
| Q3 25 | $-4.6M | $-61.9M | ||
| Q2 25 | $-1.4M | $-70.9M | ||
| Q1 25 | $-35.1M | $6.1M | ||
| Q4 24 | $-1.1M | $-51.2M | ||
| Q3 24 | $-1.1M | $-59.6M | ||
| Q2 24 | $-1.7M | $-53.0M | ||
| Q1 24 | $-2.7M | $-63.3M |
毛利率CLPRRGNX
| Q4 25 | -5.2% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 27.8% | — | ||
| Q1 25 | -34.5% | — | ||
| Q4 24 | 28.8% | 70.2% | ||
| Q3 24 | 28.6% | 48.8% | ||
| Q2 24 | 26.8% | 52.5% | ||
| Q1 24 | 25.4% | 72.6% |
营业利润率CLPRRGNX
| Q4 25 | 21.8% | -190.0% | ||
| Q3 25 | 23.6% | -176.3% | ||
| Q2 25 | 27.7% | -296.3% | ||
| Q1 25 | -59.9% | 13.6% | ||
| Q4 24 | 28.1% | -242.1% | ||
| Q3 24 | 28.6% | -256.6% | ||
| Q2 24 | 26.8% | -251.3% | ||
| Q1 24 | 25.4% | -408.8% |
净利率CLPRRGNX
| Q4 25 | -30.4% | -221.3% | ||
| Q3 25 | -12.2% | -208.3% | ||
| Q2 25 | -3.5% | -331.8% | ||
| Q1 25 | -89.1% | 6.8% | ||
| Q4 24 | -2.9% | -241.3% | ||
| Q3 24 | -2.9% | -246.3% | ||
| Q2 24 | -4.7% | -237.7% | ||
| Q1 24 | -7.5% | -405.4% |
每股收益（稀释后）CLPRRGNX
| Q4 25 | — | $-1.30 | ||
| Q3 25 | — | $-1.20 | ||
| Q2 25 | — | $-1.38 | ||
| Q1 25 | — | $0.12 | ||
| Q4 24 | — | $-0.99 | ||
| Q3 24 | — | $-1.17 | ||
| Q2 24 | — | $-1.05 | ||
| Q1 24 | — | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $30.8M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-30.7M | $102.7M |
| 总资产 | $1.2B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CLPRRGNX
| Q4 25 | $30.8M | $230.1M | ||
| Q3 25 | $26.1M | $274.2M | ||
| Q2 25 | $32.0M | $323.3M | ||
| Q1 25 | $21.3M | $267.9M | ||
| Q4 24 | $19.9M | $234.7M | ||
| Q3 24 | $18.6M | $255.5M | ||
| Q2 24 | $20.3M | $290.4M | ||
| Q1 24 | $21.9M | $338.7M |
总债务CLPRRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $1.2B | — | ||
| Q1 24 | $1.2B | — |
股东权益CLPRRGNX
| Q4 25 | $-30.7M | $102.7M | ||
| Q3 25 | $-25.0M | $161.5M | ||
| Q2 25 | $-21.9M | $213.7M | ||
| Q1 25 | $-20.1M | $274.2M | ||
| Q4 24 | $-5.4M | $259.7M | ||
| Q3 24 | $-3.6M | $301.4M | ||
| Q2 24 | $-1.8M | $348.3M | ||
| Q1 24 | $279.0K | $390.7M |
总资产CLPRRGNX
| Q4 25 | $1.2B | $453.0M | ||
| Q3 25 | $1.2B | $525.2M | ||
| Q2 25 | $1.2B | $581.0M | ||
| Q1 25 | $1.3B | $490.9M | ||
| Q4 24 | $1.3B | $466.0M | ||
| Q3 24 | $1.3B | $519.1M | ||
| Q2 24 | $1.3B | $569.4M | ||
| Q1 24 | $1.3B | $629.2M |
负债/权益比CLPRRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 4396.73× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $22.6M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流CLPRRGNX
| Q4 25 | $22.6M | $-52.3M | ||
| Q3 25 | $1.4M | $-56.0M | ||
| Q2 25 | $8.4M | $-49.3M | ||
| Q1 25 | $6.7M | $33.6M | ||
| Q4 24 | $31.9M | $-31.6M | ||
| Q3 24 | $6.3M | $-40.5M | ||
| Q2 24 | $8.8M | $-45.5M | ||
| Q1 24 | $6.3M | $-55.5M |
自由现金流CLPRRGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | $-4.6M | $32.6M | ||
| Q4 24 | $-37.9M | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | $-14.7M | $-56.0M |
自由现金流率CLPRRGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | -11.7% | 36.6% | ||
| Q4 24 | -99.5% | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | -41.1% | -358.5% |
资本支出强度CLPRRGNX
| Q4 25 | — | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | 28.6% | 1.2% | ||
| Q4 24 | 183.3% | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | 58.6% | 3.6% |
现金转化率CLPRRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLPR
| Residential Segment | $30.8M | 83% |
| Commercial Real Estate | $6.2M | 17% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
